Anbei habe ich euch 2 kleine Artikel kopiert, für alle $BMY (-0,66 %)
$TEM (-0,53 %) oder $AZN (+2,17 %) Investoren.
Ich bin selber in $BMY (-0,66 %) investiert und bin gespannt was die Zukunft bringt.
1.
23 —> Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb $BMY (-0,66 %) and Tempus AI $TEM (-0,53 %) to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.
Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors.
Here are some other details:
- Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology
- Pathos will license the data from Tempus under a five-year, $55 million agreement
- Pathos will apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials
- Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year exclusive rights to use the platform for its neuroscience development programs
- Proceeds from the financing will be used to further scale the Foundry platform's capabilities and accelerate development of its AI-driven pipeline, including advancing experimental cancer drug, JSKN016
- The funding will help advance development of other cancer programs including an AstraZeneca $AZN (+2,17 %) partnered experimental breast cancer drug.
2.
Oct 23 —> Bristol Myers Squibb $BMY (-0,66 %) and partner SystImmune said on Friday their experimental breast cancer treatment slowed disease progression compared to standard chemotherapy in a late-stage study.
The drug, izalontamab brengitecan, reduced the risk of disease worsening or death by 59% in patients with advanced hormone-receptor-positive, HER2-negative breast cancer — the most common form of breast cancer — who had failed at least one prior line of chemotherapy.
Izalontamab brengitecan belongs to a class of treatments known as antibody-drug conjugates, often called "guided missiles". It targets two specific proteins, EGFR and HER3, to deliver a cancer-killing payload directly to tumor cells.
In the study, which enrolled 383 patients, those treated with the drug lived for a median of 8.2 months without their cancer growing, compared to four months for the participants on standard chemotherapy.
About 40.5% of patients on iza-bren saw their tumors shrink, compared to 20.2% on chemotherapy. The response lasted a median of 6.9 months, versus 4.2 months for chemotherapy.
Data on overall survival, how long patients lived in total, was not yet mature at the time of the interim analysis. The full results will be presented at the European Society for Medical Oncology congress in Madrid.
Bristol Myers had partnered with SystImmune, a unit of Chinese drugmaker Sichuan Biokin Pharmaceutical, in an up to $8.4 billion deal announced in 2023 to develop and commercialize the drug outside mainland China.
Its side effects were manageable and no new safety concerns emerged, Bristol Myers said. Only 1.6% of patients stopped treatment because of side effects, while two patients developed mild-to-moderate lung inflammation.
Liebe Grüße 🌊
